Idogen reaches formal granting of patent in Japan
Idogen AB (”Idogen”) today announces that the Japan Patent Office (“JPO”) has granted the company’s patent application. The patent provides Idogen’s vaccine technology with a broad protection and further strengthens the company’s patent portfolio in an important market.The Japan Patent Office has now formally granted Idogen’s Patent Application covering induction of IDO for treatment of autoimmune diseases and transplant rejection. The patent, granted with patent number 6063392, belongs to Idogen’s second patent family and broadly covers Idogen’s technology in Japan until 2031. Related